Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04361058
Title Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.